topotecan has been researched along with Rhabdomyosarcoma, Embryonal in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Capra, M; Chew, S; Daly, P; Gleeson, JP; Grant, C; McCarthy, A; McDermott, M; Nicholson, S; O'Dwyer, R; Owens, C; Watson, GA | 1 |
| Anderson, JR; Arndt, CA; Donaldson, SS; Hawkins, DS; Lyden, ER; Morris, CD; Rodeberg, DA; Wolden, SL | 1 |
| Armeanu-Ebinger, S; Bonin, M; Fuchs, J; Poths, S; Ruck, P; Seitz, G; Warmann, SW | 1 |
| Blazar, BR; Krieg, AM; Rodeberg, DA; Weigel, BJ | 1 |
| Breneman, J; Crist, W; Lyden, E; Meza, J; Pappo, AS; Teot, L; Vietti, T; Wiener, E | 1 |
2 trial(s) available for topotecan and Rhabdomyosarcoma, Embryonal
| Article | Year |
|---|---|
Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Disease Progression; Disease-Free Survival; Female; Humans; Infant; Lymph Nodes; Male; Meningeal Neoplasms; Radiotherapy Dosage; Retroperitoneal Neoplasms; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Topotecan; Treatment Failure; Tumor Burden; Vincristine | 2015 |
Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Male; Rhabdomyosarcoma; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Survival Rate; Topotecan | 2001 |
3 other study(ies) available for topotecan and Rhabdomyosarcoma, Embryonal
| Article | Year |
|---|---|
Leptomeningeal Relapse of Embryonal Rhabdomyosarcoma after 15 years.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Child, Preschool; Cyclophosphamide; Ear Neoplasms; Humans; Male; Meningeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy Dosage; Rare Diseases; Rhabdomyosarcoma, Embryonal; Time Factors; Topotecan; Treatment Outcome; Young Adult | 2020 |
Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression; Gene Expression Profiling; Glutathione Transferase; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Topotecan; Vincristine; Xenograft Model Antitumor Assays | 2010 |
CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; CpG Islands; Cyclophosphamide; Disease Models, Animal; Drug Synergism; Female; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Oligonucleotides; Rhabdomyosarcoma, Embryonal; T-Lymphocytes; Time Factors; Topotecan | 2003 |